Treatment Challenges and Solutions in cGVHD

Leyla O. Shune, MD, discusses the challenge of managing patients with heavily pretreated chronic graft-versus-host disease (cGVHD) and explains the significance of targeting the underlying profibrotic pathways. She highlights the emergence of axatilimab, a CSF-1R inhibitor that attacks the underlying mechanisms of cGVHD by targeting proinflammatory and profibrotic monocytes and macrophages.